Publication

Atezolizumab (atezo) plus bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis

Rini, BI
; 
Motzer, RJ
; 
Powles, T
; 
McDermott, DF
; 
Escudier, B
; 
Donskov, F
; 
Hawkins, Robert E
; 
Bracarda, S
; 
Bedke, J
; 
De Giorgi, U
... show 10 more
Citations
Altmetric:
Abstract
Authors
Rini, BI
Motzer, RJ
Powles, T
McDermott, DF
Escudier, B
Donskov, F
Hawkins, Robert E
Bracarda, S
Bedke, J
De Giorgi, U
Porta, C
Ravaud, A
Parnis, F
Grande, E
Zhang, W
Huseni, MA
Carroll, S
Sufan, RI
Schiff, C
Atkins, MB
Affiliation
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Rini BI, Motzer RJ, Powles T, McDermott DF, Escudier B, Donskov F, et al. Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis. J Clin Oncol. 2019;37(15_suppl):4512-.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622464
Embedded videos